This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Financial Calendar
Results for the Six Months Ended 30 June 2023
14 September 2023
- Presentations
- Financial Reports
- Corporate Videos
- Analyst Reports
View
Interim results for the six months ended 30 June 2023
14 September 2023
Preliminary Results for The Year Ended 31 December 2022
20 April 2023
Interim results for the six months ended 30 June 2022
8 September 2022
Preliminary Results for The Year Ended 31 December 2021
25 April 2022
Interim results for the six months ended 30 June 2021
23 September 2021
Interim results for the six months ended 30 June 2023
14 September 2023
Interim results for the six months ended 30 June 2022
8 September 2022
Arecor Therapeutics Annual Report and Accounts 2021
27 April 2022
Final results for the year ended 31 December 2021
25 April 2022
Interim results for the six months ended 30 June 2023
23 September 2021
15 September 2023
Interim results for the six months ended 30 June 2023
14 September 2023
20 April 2023
7 March 2023
14 February 2023
15 November 2022
12 October 2022
Interim results for the six months ended 30 June 2021
23 September 2021
Analyst research is also written by Panmure Gordon and Singer Capital Markets.
Trinity Delta – Growth plans starting to stack up
14 September 2023
Trinity Delta – Pipeline and partnership progress
20 July 2023
Trinity Delta – Hikma licence milestone achieved
13 January 2023
Trinity Delta – Getting the chemistry right
20 December 2022
Trinity Delta – Broadening opportunities and preparing for the future
21 September 2022
Trinity Delta – Key clinical diabetes events on track for H2 2022
8 September 2022
Trinity Delta – AT278 hits the sweet spot
31 May 2022